Use of isoniazid for latent tuberculosis infection in a public health clinic.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2003-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/RCCM.200303-390OCPMID 12746255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.

  2015cited by this paper
• Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.

  2003influential reference
• Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.

  2002cited by this paper
• Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

  2002cited by this paper
• Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.

  2001cited by this paper
• Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.

  2000cited by this paper
• Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

  1999cited by this paper
• How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

  1999cited by this paper
• Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.

  1998influential reference
• Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

  1994cited by this paper
• Toxic hepatitis with isoniazid and rifampin. A meta-analysis.

  1991cited by this paper
• Efficacy of various duration of isoniazid preventive therapy for tuberculosis : five years follow-up in the IUAT trial

  1982cited by this paper
• Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.

  1982cited by this paper
• Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

  1978cited by this paper
• Isoniazid-associated hepatitis. Report of an outbreak.

  1972cited by this paper
• Controlled chemoprophylaxis trials in tuberculosis. A general review.

  1970cited by this paper
• Controlled chemoprophylaxis trials in tuberculosis. A general review.

  1970cited by this paper

• Latent Tuberculosis Screening and Active Tuberculosis Disease Development in People Living with HIV: A Multicenter Retrospective Cohort Study in Turkiye.

  2025cites this paper
• Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents

  2025cites this paper
• Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases

  2025cites this paper
• Safety, efficacy and feasibility of preventive treatment for drug-resistant tuberculosis with moxifloxacin or bedaquiline

  2025influential citation
• Factors associated with incomplete tuberculosis preventive treatment: a retrospective analysis of six-years programmatic data in Cambodia

  2024cites this paper
• Topical isoniazid as a novel treatment for melasma: A randomized, double‐blind, vehicle‐controlled clinical trial

  2024cites this paper
• Prediction and Rationalization of Abundant C-N-H Molecules in Different Environments.

  2023cites this paper
• Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial

  2023cites this paper
• Construction of isoniazid pharmaceutical logic system based on poly(N, N-diethylacrylamide) hydrogel films

  2023cites this paper
• Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study

  2022cites this paper
• Pharmacokinetics of isoniazid in Wistar rats exposed to ethanol

  2022cites this paper
• Outcomes of latent tuberculosis infection treatment in Istanbul

  2022cites this paper
• Equilibrium molecular structure and intramolecular interactions of picolinic acid hydrazide

  2022cites this paper
• An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013-2020)

  2021cites this paper
• The Drinkers’ Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial

  2021cites this paper
• Evaluation of the Dispensing Rate of Isoniazid Used in the Preventive Treatment of Tuberculosis in a Service Specialized in HIV / AIDS

  2021cites this paper
• Molecular Insights into the Interaction of Ursolic Acid and Cucurbitacin from Colocynth with Therapeutic Targets of Mycobacterium tuberculosis

  2020cites this paper
• QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results

  2020cites this paper
• Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB

  2020cites this paper
• Addressing Latent Tuberculosis Infection Treatment Through a Collaborative Care Model With Community Pharmacies and a Health Department

  2020cites this paper
• Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: analysis of Japan Tuberculosis Surveillance data

  2020cites this paper
• Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues.

  2020cites this paper
• Risk factors affecting the failure to complete treatment for patients with latent tuberculosis infection in Tokyo, Japan.

  2020cites this paper
• Evaluation of hepatotoxicity in elderly with HIV/AIDS using isoniazid

  2020cites this paper
• Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: retrospective analysis of Japan tuberculosis surveillance data

  2020cites this paper
• Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda

  2020cites this paper
• Avaliação de hepatotoxicidade em idosos com HIV/AIDS em uso de isoniazida

  2020cites this paper
• Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.

  2019cites this paper
• Failure to complete treatment for latent tuberculosis infection in Portugal, 2013–2017: geographic-, sociodemographic-, and medical-associated factors

  2019cites this paper
• Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil

  2019cites this paper
• Drug-induced liver injury

  2019cites this paper
• Modelling the impact of incipient tuberculosis testing

  2019cites this paper
• Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness

  2019cites this paper
• British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019

  2019cites this paper
• Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature

  2018cites this paper
• Cost-effectiveness analysis of programmatic screening strategies for latent tuberculosis infection in the EU/EEA

  2018cites this paper
• Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis

  2018cites this paper
• Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing

  2018cites this paper
• Preventing Tuberculosis in a Low Incidence Setting: Evaluation of a Multi-lingual, Online, Educational Video on Latent Tuberculosis

  2018cites this paper
• Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics

  2018cites this paper
• Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings

  2018cites this paper
• Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs

  2018cites this paper
• Tuberculosis mastitis presenting as bilateral breast masses.

  2018cites this paper
• Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area

  2018cites this paper
• Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.

  2018cites this paper
• High rate of latent tuberculosis treatment completion in immigrants seeking asylum in Sweden

  2018cites this paper
• Treatment of Latent Tuberculosis Infection

  2017influential citation
• Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk–Benefit Analysis

  2017cites this paper
• Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children

  2017cites this paper
• Preventive Therapy Against Tuberculosis

  2017cites this paper
• Tuberculosis Contact Investigation in an Urban Omaha High School

  2017cites this paper
• Adherence to Latent Tuberculosis Infection Treatment in a Population with a High Number of Refugee Children.

  2017cites this paper
• Tuberculosis Prevention in the Private Sector: Using Claims-Based Methods to Identify and Evaluate Latent Tuberculosis Infection Treatment With Isoniazid Among the Commercially Insured

  2017cites this paper
• Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist

  2017cites this paper
• Trend and treatment status of latent tuberculosis infection patients in Japan – Analysis of Japan TB Surveillance data

  2017cites this paper
• High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection

  2017cites this paper
• Gene therapy based in antimicrobial peptides and proinflammatory cytokine prevents reactivation of experimental latent tuberculosis.

  2016cites this paper
• Beyond pills and tests: addressing the social determinants of tuberculosis.

  2016cites this paper
• Latent Tuberculosis Infection Among Immigrant and Refugee Children Arriving in the United States: 2010

  2016cites this paper
• Initiation and completion rates for latent tuberculosis infection treatment: a systematic review

  2016cites this paper
• The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature

  2016cites this paper
• Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review

  2016cites this paper
• Baseline abnormal liver function tests are more important than age in the development of isoniazid‐induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection

  2016cites this paper
• Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada.

  2016cites this paper
• Factors Affecting Medication Adherence among Vietnamese Immigrants with Latent Tuberculosis Infection: A Mixed Design

  2016cites this paper
• Adherence to latent tuberculosis treatment among immigrants in low endemic settings : a scoping review

  2016cites this paper
• Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.

  2016cites this paper
• Isoniazid-resistant tuberculosis in Iran: A systematic review.

  2016cites this paper
• Running Head : FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 1 Factors Affecting Uptake of , and Adherence to , Treatment for Latent Tuberculosis Infection in Ventanilla , Peru

  2015cites this paper
• Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years.

  2015cites this paper
• To eliminate tuberculosis, we must universally encourage treatment of its latent form

  2015cites this paper
• Medication adherence challenges among patients experiencing homelessness in a behavioral health clinic.

  2015cites this paper
• Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.

  2015cites this paper
• Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.

  2015cites this paper
• Pathways and costs of care for patients with tuberculosis symptoms in rural Uganda.

  2015cites this paper
• Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy

  2015cites this paper
• Treatment of Latent Tuberculosis Infection

  2015cites this paper
• A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.

  2015cites this paper
• Clinical peculiarities of tuberculosis

  2014cites this paper
• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

  2014cites this paper
• A study of epidemiology and clinical profile of tuberculosis in patients living with HIV-AIDS -

  2014influential citation
• Isoniazid Hepatotoxicity Requiring Liver Transplantation

  2014cites this paper
• Prevalence of Drug-Induced Hepatitis and its Risk Factors in the Treatment of Tuberculosis in TB Infected Patients Attending Razi Hospital, 2006-2011

  2014cites this paper
• Cinnamic acid hydrogen bonds to isoniazid and N'-(propan-2-ylidene)isonicotinohydrazide, an in situ reaction product of isoniazid and acetone.

  2014cites this paper
• Economics of United States tuberculosis airline contact investigation policies: a return on investment analysis.

  2014cites this paper
• Drugs used in tuberculosis and leprosy

  2014cites this paper
• Factors associated with noncompletion of latent tuberculosis infection treatment in an inner-city population in Edmonton, Alberta

  2014cites this paper
• Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients

  2014cites this paper
• Short-Course Isoniazid Plus Rifapentine Directly Observed Therapy for Latent Tuberculosis in Solid-Organ Transplant Candidates

  2014cites this paper
• Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection.

  2014cites this paper
• Risk factors for treatment default in close contacts with latent tuberculosis infection

  2014cites this paper
• Update on latent tuberculosis infection.

  2014cites this paper
• Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study.

  2014cites this paper
• Successful Management of Latent Tuberculosis Infection in an Underserved Community by a Student-run Free Clinic

  2014cites this paper
• Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents.

  2014cites this paper
• Impact of Prescription Patterns on Compliance With Follow-Up Visits at an Urban Teaching Primary Care Continuity Clinic

  2014cites this paper
• Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.

  2014cites this paper
• Effects of Patient Self-Selection on Costs to Treat Latent Tuberculosis Infection (LTBI)

  2014cites this paper
• Risk factors for treatment default in close contacts with latent tuberculous infection.

  2014cites this paper
• Quantitative methods to support drug benefit-risk assessment

  2014cites this paper